Abstract
Severe thrombocytopenia in association with G-CSF therapy is extremely rare. Here we report a case of profound thrombocytopenia in a 57-year-old male with refractory cardiac ischemia, who received G-CSF during an angiogenesis trial. After 5 days of G-CSF therapy (10 microg/kg/day) the platelet count fell progressively to a nadir of 5x10(9)/L. The patient received steroid, immunoglobulin and platelet support and recovered without sequelae. Subsequent investigations suggested an underlying immune-mediated thrombocytopenia, which we hypothesize was exacerbated by G-CSF therapy.
Copyright (c) 2006 Wiley-Liss, Inc.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Blood Cell Count
-
Granulocyte Colony-Stimulating Factor / administration & dosage
-
Granulocyte Colony-Stimulating Factor / adverse effects*
-
Granulocyte Colony-Stimulating Factor / therapeutic use
-
Humans
-
Male
-
Middle Aged
-
Myocardial Ischemia / blood
-
Myocardial Ischemia / drug therapy
-
Myocardial Ischemia / immunology
-
Purpura, Thrombocytopenic, Idiopathic / chemically induced*
-
Purpura, Thrombocytopenic, Idiopathic / immunology
-
Recombinant Proteins
-
Severity of Illness Index
Substances
-
Recombinant Proteins
-
Granulocyte Colony-Stimulating Factor